Tesamorelin vs Epithalon
Head-to-head comparison of Tesamorelin and Epithalon for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Tesamorelin | Epithalon |
|---|---|---|
| Category | Growth Hormone Secretagogue | Anti-Aging / Telomere |
| Mechanism | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. | Epithalon (C14H22N4O9, MW ~390 daltons) activates telomerase, particularly the catalytic subunit TERT (telomerase reverse transcriptase), extending telomeres at chromosome ends. |
| Evidence Rating | A — FDA Approved | D — Preclinical |
| Clinical Status | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy | Research-only / No approved human indication in Western countries |
| Safety Profile | Headache, nausea, and flu-like symptoms reported; May increase blood glucose -- monitoring recommended in diabetics | Generally well tolerated; no serious adverse events reported in decades of Russian clinical use; Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported |
| Molecular Weight | ~5135.9 g/mol | ~390.3 g/mol |
| Half-Life | ~26–38 minutes | Several hours |
Overview
Tesamorelin and Epithalon are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Tesamorelin — Mechanism & Evidence
It stimulates endogenous GH and IGF-1 production. Phase 3 trials demonstrated significant visceral fat reduction with a generally well-tolerated safety profile over 26 weeks of therapy.
Key claims: Reduces visceral adipose tissue in HIV lipodystrophy; Increases skeletal muscle area and density; Effective on INSTI-based HIV regimens.
Tesamorelin 10mg
10mg
Epithalon — Mechanism & Evidence
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, MW ~390 g/mol) developed by Russian gerontologist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary mechanism involves telomerase activation to maintain telomere length. Secondary mechanisms include melatonin enhancement via pineal gland restoration, hormonal balance improvement, and antioxidant defense. Extensive Russian research spanning 20+ years of clinical use reports safety and efficacy, but Western clinical trials remain minimal. Animal studies show lifespan extension of up to 13.3% in the last 10% of survivors (p<0.05).
Key claims: Activates telomerase and extends telomeres; Extends lifespan in animal models; Restores melatonin production and sleep quality.
Shared Research Applications
These peptides target different research areas. Tesamorelin focuses on Body Composition, while Epithalon targets Anti-Aging.
Safety Considerations
Tesamorelin: Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics FDA pregnancy category X -- tesamorelin can harm an unborn baby or cause birth defects
Epithalon: Generally well tolerated; no serious adverse events reported in decades of Russian clinical use Good safety margin: doses studied range from 0.5 to 5 mg with no dose-limiting toxicity reported Mild headaches, dizziness, and GI discomfort possible
Shop Research Peptides
Tesamorelin 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
Tesamorelin Research Interest Grows Among Synthetic GHRPs
Synthetic growth hormone-releasing peptides (GHRPs) are drawing increasing attention in scientific research, with tesamorelin emerging as a focal point. The compound, a synthetic analog of growth hormone-releasing hormone, is being studied for its potential to modulate growth hormone levels. This article examines the rising research interest in tesamorelin and its place within the broader class of synthetic GHRPs.